SS
AMRX icon

Steve Schonfeld’s Amneal Pharmaceuticals AMRX Stock Holding History

Steve Schonfeld’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3M Buy
305,991
+269,189
+731% +$3.69M 0.02% 630
2026
Q1 		$457K Buy
+36,802
New +$494K ﹤0.01% 1421
2025
Q3 		– Sell
-53,771
Closed -$435K – 2175
2025
Q2 		$435K Buy
53,771
+40,871
+317% +$308K ﹤0.01% 1593
2025
Q1 		$108K Buy
+12,900
New +$108K ﹤0.01% 2013
2023
Q3 		– Sell
-23,700
Closed -$73.5K – 1749
2023
Q2 		$73.5K Sell
23,700
-300
-1% -$639 ﹤0.01% 1768
2023
Q1 		$33.4K Sell
24,000
-4,900
-17% -$9.76K ﹤0.01% 1805
2022
Q4 		$57.5K Sell
28,900
-3,452
-11% -$7.74K ﹤0.01% 2253
2022
Q3 		$65K Buy
+32,352
New +$90.7K ﹤0.01% 2608
2021
Q2 		– Sell
-61,567
Closed -$414K – 1915
2021
Q1 		$414K Buy
61,567
+27,067
+78% +$150K 0.01% 1211
2020
Q4 		$157K Buy
+34,500
New +$153K ﹤0.01% 1386
2018
Q4 		– Sell
-188,700
Closed -$4.19M – 1044
2018
Q3 		$4.19M Buy
188,700
+125,828
+200% +$2.65M 0.19% 155
2018
Q2 		$1.03M Buy
+62,872
New +$1.1M 0.06% 386

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Steve Schonfeld's AMRX Position: Q2 2026 in Review

Steve Schonfeld increased its Amneal Pharmaceuticals (AMRX) stake by 731% in Q2 2026, buying an estimated $3.69M and bringing the position to 305,991 shares worth $5.3M. The position accounts for 0.02% of the portfolio, ranked #630.

Steve Schonfeld first reported a position in AMRX in Q2 2018 and has held it in 12 quarters since. 305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Steve Schonfeld held 305,991 shares of Amneal Pharmaceuticals worth $5.3M as of Q2 2026.
  • Steve Schonfeld bought 269,189 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.69M.
  • Amneal Pharmaceuticals made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #630 holding.
  • Steve Schonfeld first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
  • 305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.